The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
China
Wuhan Union Hospital, Wuhan, Hubei Tianjin Institute of Hematology, Tianjin, Tianjin Municipality The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang Last updated November 2025